

## DAFTAR PUSTAKA

1. Djaafar ZA, Helmi, Restuti RD. Kelainan telinga tengah. Dalam Buku Ajar Ilmu Kesehatan Telinga Hidung Tenggorok Kepala dan Leher FKUI.Jakarta 2012;p 57-69
2. William H, Slattery I. Pathology and diseases of the middle ear.In Glasscock-Shambough Surgery of the ear. BC Denker Inc. Spain.2003;p 422-33.
3. Sandeep S, Raghavendra KS, Prakash BG, Shetty TS. How safe is safe ear?: a hospital based study. Int J Sci. 2014;2(2):31-4.
4. Data G, Baisakhiya N, Mendiratta V. Unsafe CSOM still a chalange in rural areas. Otolaryngol. 2014;4(2): 1-3
5. Baig MM, Ajmal M, Saeed I, Fatima S. Prevalance of cholesteatoma and its complications in patients of chronic suppurative otitis media. JRMC. 2011; 15(1):16-7.
6. Aduda DSO, Macharia IM, Mugwe P, Oburra H, Faragher B. Bacteriology of chronic suppurative otitis media (CSOM) in children in garissa district, kenya: a point prevalence study. Int J Ped Otolaryngol. 2013:1-5.
7. Uddin W, Hussain A, Khan A, Ahmad F, Samiullah. Prevalence and comparison of chronic suppurative otitis media in government and private schools. Ann Pak Ins Med Sci.2009;5(3): 141-4
8. Helmi. Otitis media supuratif kronis. Dalam otitis media supuratif kronis. Jakarta: Balai penerbit FKUI ;2005: 55-68
9. Arts HA, Adams ME. Intratemporal and intracranial complications of otitis media. In : Bailey B.J, Jhonson J.T Newslands S.D. Head and Neck Surgery- Otorhinolaryngology.5<sup>th</sup> edition.Philadelphia: Lippincott William and Wilkins 2014;p 2399-408
10. Quinn FB, Ryan MW. Cholesteatoma. Grand Round Presentation, UTMB,Dept.of. Otolaryngol.2002:1-9.
11. Meyer TA, Strunk CL, Lambert PR. Cholesteatoma. In: Bailey B.J, Jhonson J.T Newslands S.D. Head and Neck Surgery- Otorhinolaryngology.5<sup>th</sup> edition.Philadelphia: Lippincott William and Wilkins 2014:p 2434-45.

12. Dornelles C, Costa SS, Meurer L, Schweiger C. Some considerations about acquired adult and pediatric cholesteatoma. *Braz J otolaryngol.* 2005;71(4):536-46.
13. Quinn MS, Quinn FB, Young D, Son E. Cholesteatoma. Grand round presentation, head and neck surgery UTMB health. Dept of Otolaryngol. 2013:1-5.
14. Chang P, Kim S. Cholesteatoma-diagnosing the unsafe ear. *Australian family physician.* 2008;37(8):631-8
15. Olszewska E, Wagner M, Sprekelsen BM, Ebmeyer J, Dazert S, Hildmann H, et al. Etiopathogenesis of cholesteatoma. *Eur Arch Otorhinolaryngol.* 2004;261:6-24.
16. Nevoux J, Lenoir M, Roger G, Denoyelle F, Pointe L, Garabedian EN. Childhood cholesteatoma. *European annals of otorhinolaryngology, head and neck disease.* 2010;127:143-50
17. Vital V, Bitaa B. Pediatric cholesteatoma: personal experience and review of the literature. *Otolaryngol head and neck surg.* 2011;45:5-14.
18. Edfeldt L. Middle ear cholesteatoma. *Digital comprehensive summaries of Uppsala Dissertations from the Faculty of Medicine 905.* 2013:11-8.
19. Kuczkowski J, Burkiewicz MS, Swieszewska EI. Expression of the receptor activator for nuclear factor- $\kappa$ B ligand and osteoprotegerin in chronic otitis media. *American J Otol.* 2010:404-9.
20. Frickmann H, Zautner AE. Cholesteatoma-a potential consequence of chronic middle ear inflammation. *Otolaryngology journal.* 2012;1-8
21. Shaik Y, Anagianaki A, Katsanos GS, Castellani ML, Frydas S, Vecchiet J, et al. Role of cytokines in the pathogenesis of bone resorption. *J of Orth.* 2009;1(1):25-8
22. Maniu A, Haragabiu O, Schrepler MP, Catana A, Fanuta B, Mogoanta CA. et al. Molecular biology of cholesteatoma. *Rom J Morphol Embryol.* 2014;55(1):7-13.
23. Vitale RF, Andrade F, Ribeiro Q. The role of Tumor Necrosis Factor- Alpha (TNF- $\alpha$ ) in bone resorption present in middle ear cholesteatoma. *Braz J otorhinolaryngol.* 2007;73 (1):123-7.

24. Chu WM. Tumor necrosis factor. Cancer biology program. Universitas of Hawaii Cancer Center 2013;328(2):222-5.
25. Kuczkowski J, Burkiewicz MS, Swieszewska EI, Mikaszewki B, Pawelczyk T. Expression of Tumor Necrosis Factor- $\alpha$ , Interleukin-1 $\alpha$ , Interleukin-6 and Interleukin-10 in chronic otitis media with bone osteolysis. *ORL*.2011;73:93-9.
26. Liu W, Xie S, Chem X, Rao X, Ren H, Hu B, et al. Activation of the IL-6/JAK/STAT3 signaling pathway in human middle ear cholesteatoma epithelium. *Int J Clin Exp Pathol*.2014;7(2):709-15
27. Britze A, Palmfeldt J, Gregersen N, Ovesen T. 44-plex cytokines profile of cholesteatoma. *Acta oto laryngologica*.2014;134:41-50
28. Scheller J, Chalaris A, Arras DS, John SR. The pro-and anti-inflammatory properties of the cytokine interleukin-6. *Biochimica et Biophysica acta*.2011;878-88
29. Kuo CL, Shiao AS, Yung M, Sakagami M, Sudhoff H, Wang CH, et al. Update and knowledge gaps in cholesteatoma research. *BioMed Research Int*.2015:1-12.
30. Kuo CL. Etiopathogenesis of acquired cholesteatoma: prominent theories and recent advances in biomolecular research. *Laryngoscope*.2014:1-7.
31. Sinha AK, Kumar A, Ahmad E, Raushan, Kumar G. Bone Resorption in chronic otitis media. *Int J Sci study*.2014;2(6):82-5.
32. Roslenda AR, A Asma, FRW Iqbal, J Jeevanan. Congenital or acquired? a case report of extensive congenital cholesteatoma. *Med&Health*.2010;5(2):103-7.
33. Barath K, Huber AM, Stampfli P, Varga Z, Kollias S. Neuroradiology of cholesteatomas. *AJNR Am J Neuroradiology*.2011;32:221-9.
34. Chole RA, Nason R. Chronic otitis media and cholesteatoma. In : *Ballengers manual of otorhinology head and neck surgery*, BC Decker.2009;p:217-27
35. Jackler RK, Maria PLS, Varsak YK, Nguyen A, Blevins NH. A new theory on the pathogenesis of acquired cholesteatoma : Mucosal traction. *The laryngoscop*. 2015:125:1-12
36. Aljfout QM, Alruhaibeh MK, Naghawry WR, Alrawabdeh SM, Alzaibaneen SI, Alkhalaylah KK et al. Acquired cholesteatoma of the ear ; comparative

- analysis of histopathological findings in adults, children and recurrent cases. *JRMS*.2012;19(1):41-5.
37. Kanemaru SC, Kikkawa Y, Omori K, Ito J. Bone destructive mechanisms of cholesteatoma. Department of Otolaryngology HNS, Kyoto University. Japan
38. Masanta WO, Hinz R, Zautner AE. Infectious causes of cholesteatoma and treatment of infected ossicles prior to reimplantation by hydrostatic high pressure inactivation. *BioMed research international*.2015:1-5.
39. Kaya E, Dag I, Incesulu A, Gurbuz MK, Acar M, Birdane L. investigation of the presence of biofilms in chronic suppurative otitis media, non suppurative otitis media, and chronic otitis media with cholesteatoma by scanning electron microscopy. *The scientific world jurnal*.2013:1-6.
40. Anantharajah A, Buyck JM, Faure E, Glupczynski Y, Villalobos HR, Vos DD, et al. correlation between cytotoxicity induced by *Pseudomonas aeruginosa* clinical isolates from acute infections and IL-1 $\beta$  secretion in a model of human THP-1 monocytes. *FEMS J*.2015;73:1-4.
41. Aquino JEAP, Filho NAC, Aquino JNP. Epidemiology of middle ear and mastoid cholesteatomas: Study of 1146 cases. *BJORL J Otorhinolaryngol*.2011;77(3):341-7.
42. Wei S, Kitaura H, Zhou P, Ross FP, Teitelbaum SL. IL-1 mediates TNF-induced osteoclastogenesis. *The journal of clinical investigation*. 2005;115(2):282-90.
43. Aggarwal BB, Gupta SC, Kim JH. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. *Am socie hema*. 2012;119(3):651-65.
44. Dahlan S. Menggunakan rumus besar sampel secara benar dalam besar sampel dan cara pengambilan sampel. Edisi 2. Salemba Medika Jakarta.2009.33-78.
45. Mustafa A, Kuci S, Behramaj A. Management of cholesteatoma complication: our experience 145 cases. *Indian J Otol* .2014;20:45-7
46. Panchasara A, Singh A, Mandavia D, Jha S, Tripathi C. Efficacy and safety of ofloxacin and its combination with dexamethasone in chronic suppurative otitis media. A randomized, double blind, parallel group, comparative study. *Acta Otorhinolaryngologica Italica*.2015;35:39-44

47. Rosito LPS, Silva MNL, Selaiman FA, Jung YP, Pauletti MGT, Jung LP, et al. Characteristic of 419 patients with acquired middle ear cholesteatoma. *Braz J Otorhinolaryngol*.2016;(2):1-6
48. Widyatama IKH, Handoko E, Wahyudiono AD. Hubungan kadar IL-6 kolesteatomadengan derajat kerusakan tulang pendengaran pasien otitis media supuratif kronis. *ORLI*.2014;44(2):83-95
49. Artono, Purnani N, Rahmawati R. Biofilm bacterial plays a role in csom pathogenesis and has significant correlation with unsafe type csom. *Medica Indonesia*.2015;51(4):208-13
50. Yousuf M, Majumder KA, Kamal A, Shumon AM, Zaman Y. Clinical study on chronic otitis media suppurative with cholesteatoma. *Bangladesh J Otorhinolaryngol* 2011; 17(1): 42-7
51. Asroel HA, Siregar DR, Aboet A. Profil of patient with chronic suppurative otitis media. *Jurnal Kesehatan Masyarakat Nasional*.2013;7(12):567-71
52. Benson J, Mwarni L. Chronic suppurative otitis media and cholesteatoma in Australia's refugees population. *Research. Australia family physician*. 2012;41(12);978-80
53. Madana J, Yolmo D, Kalaiarasi R, Gopalakrishnan S, Sujatha S. Microbiological profile with antibiotic sensitivity pattern of cholesteatomatous chronic suppurative otitis media. *Int J Ped otorhinolaryngol*.2011;75:1104-08
54. Bustin SA. Quantification of mRNA using real time reverse transcription (RT-PCR): trends and problems. *J Mol Endocrinol* 2002;29:23-9
55. Dako. Immunohistochemical staining methods. Editor Kumar GL, Rudbeck L, Pathology education guide, Fifth edition 2009.p.1-160
56. Prins JM, Kuiper EJ, Mevissen MCCM, Speelman P, Deventer SJH. Release of tumor necrosis factor alpha and interleukin-6 during antibiotic killing of *Escherichia coli* in whole blood: Influence of antibiotic class, antibiotic concentration and presence of septic serum. *American society for microbiology*. 1995;63(6):2236-42
57. Eide DS, Ohlsson C. Effect of cortisol on the expression of interleukin-6 and interleukin 1 $\beta$  in human osteoblast-like cells. *J of Endocrinology*.1998;156:107-114